Beyond traditional monitoring of kidney transplant recipients, donor derived-cell free DNA may permit early identification of graft damage.

A novel low-cost assay sequencing cell-free DNA methylome in blood demonstrates strong performance across a range of clinical applications.

When cells in the body die, they release DNA. This DNA, known as cell-free DNA (cfDNA), makes its way into the bloodstream where it gets chopped up by enzymes, and in minutes to hours, the liver pulls ...

A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...

Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...

Analytic and clinical validation of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA. Sintilimab plus bevacizumab, oxaliplatin, and ...

Study: Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test. Image Credit: 3dMediSphere / Shutterstock In a recent study published in the ...

Clonal, cell-free DNA with unmatched length, complexity and accuracy now available at industry-leading prices. Elegen today announced significant price reductions across its ENFINIA™ DNA portfolio, ...

When a tumor starts to grow in the body, small bits of its genetic material may break away and float off into the bloodstream. This so-called cell free DNA can be used to identify cancer at very early ...

Elegen has launched ENFINIA™ IVT Ready DNA, a cell-free gene synthesis platform that provides full-length linear DNA templates encoded poly(A) tails for in vitro transcription. The templates are ...